Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
Sponsors
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Conditions
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)
Phase 1
Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study
CompletedNCT04827056
Start: 2021-11-09End: 2023-06-02Updated: 2023-10-26
Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study
RecruitingNCT06335407
Start: 2025-07-28End: 2026-05-31Target: 10Updated: 2025-10-27